Evidence map›Paper›PMID 41688436›Full record

ArticleNature communications2026

Engineered exosome nanovesicles for delivery of antibodies to treat inflammatory bowel disease.

Jiahui Cao, Ran Luo, Rourou Miao, Wen Li, Baisong Zhu, Liu Yu, Yiqiu Fu, Xinyi Wang, Jinxie Zhang, Wenfeng Zeng and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Jiahui CaoState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Ran LuoState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Rourou MiaoState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Wen LiState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Baisong ZhuState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Liu YuState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Yiqiu FuState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Xinyi WangState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Jinxie ZhangState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Wenfeng ZengState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Hanjie ZhangState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.
Zhuo MaoState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China.ORCID http://orcid.org/0000-0001-9012-9825
Fan ZhangState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China. zhangfan@bme.pumc.edu.cn.ORCID http://orcid.org/0000-0003-3335-6321
Yao-Xin LinCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing, P.R. China. linyx@nanoctr.cn.ORCID http://orcid.org/0000-0002-4457-2495
Meitong OuState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China. oumt@bme.pumc.edu.cn.ORCID http://orcid.org/0000-0001-8622-1442
Lin MeiState Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Biomedical Materials, Beijing Key Laboratory of Key Technologies for Natural Drug Delivery and Novel Formulations, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, P. R. China. meilin@bme.pumc.edu.cn.ORCID http://orcid.org/0000-0001-6503-5149

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82272154
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is characterized by chronic inflammation and impaired immune tolerance, for which current therapies provide only partial and transient relief. Here, we introduce PrEXO-a23, a biomimetic nanotherapeutic engineered by fusing regulatory T cell (Treg)-derived exosomes with platelet membrane vesicles and conjugating interleukin-23 (IL-23) antibodies via a matrix metalloproteinase (MMP)-cleavable linker. This design exploits the inherent homing ability of platelets and Tregs, enabling PrEXO-a23 to preferentially accumulate in inflamed colonic tissues in murine IBD models. At the disease site, elevated MMP activity triggers antibody release to inhibit IL-23-mediated inflammation, while exosomal cargo reprograms dendritic cells and promotes Treg expansion, thereby restoring immune tolerance. This dual-action strategy significantly alleviates IBD, prevents complications like intestinal fibrosis and colitis-associated colorectal cancer, and shows p53-dependent efficacy in carcinogenesis prevention. These findings highlight PrEXO-a23 as a promising nanotherapeutic platform for durable immune reprogramming and long-term IBD management.

Indexed as

AntibodiesExosomesInflammatory Bowel DiseasesAnimalsColitisDisease Models, AnimalFemaleHumansInterleukin-23MiceMice, Inbred C57BLT-Lymphocytes, RegulatoryAntibodiesInterleukin-23

Identifiers

PMID41688436
PMCPMC13013668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.